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Azogabazine; a photochromic antagonist of the GABAA receptor  
Rosemary Huckvale,a Martin Mortensen,b David Pryde,c Trevor G. Smart,b,* and James R. Bakera,* 
The design and synthesis of Azogabazine is described, which represents a highly potent (IC50 = 23 nM) photoswitchable 
antagonist of the GABAA receptor.  An azologization strategy is adopted, in which a benzyl phenyl ether in a high affinity 
gabazine analogue is replaced by an azobenzene, with resultant retention of antagonist potency.  We show that cycling from 
blue to UV light, switching between trans and cis isomeric forms, leads to photochemically controlled antagonism of the 
GABA ion channel.    
GABAA receptors are ligand-gated chloride ion channels,1 which 
are activated by γ-aminobutyric acid (GABA); the major 
inhibitory neurotransmitter present in the central nervous 
system.2  GABAA receptors are also modulated by an array of 
compounds including neurosteroids, benzodiazepines and 
barbiturates.3  A number of small molecule antagonists are 
known for the GABAA receptor,4  of which gabazine (Fig. 1, also 
called SR-95531)4a, 5 is one of the most widely used.4e  Gabazine 
is a competitive antagonist (IC50 = 349 nM), and we recently 
described the development of enhanced potency analogues 
including Gz-i1 (IC50 = 13 nM).6  Furthermore, by incorporation 
of a benzophenone, we constructed a photoaffinity labelled 
version (GZ-B1, IC50 = 153 nM) which upon irradiation could be 
employed to irreversibly block populations of native neuronal 
GABAA receptors, facilitating the study of receptor trafficking.7 
We envisaged that reversible light mediated control of activity 
would offer further opportunities to probe this important class 
of ion channels.  
  Chemical photoswitches are photochromic compounds which 
can be activated and deactivated in cycles.8 These can be used 
to reversibly control the function of a biological system with 
light.9 By far the most well-known and widely-used 
photoswitches are azobenzenes, which upon irradiation with 
UV light form a cis-enriched photostationary state, which 
converts to the more stable trans isomer upon visible light 
irradiation or thermal relaxation.  Two main strategies have 
been developed to exploit the use of photoswitches to infer 
photochemical control over ion channel activity.  The first 
involves covalent attachment of ligands onto the channel, such 
that the ligand can bind in its active isomeric form, but upon 
irradiation is expelled from the binding site.  This approach is 
known as photoswitchable tethered ligands (PTL) and 
essentially serves to provide a constant high local concentration 
of the ligand.9  The second strategy involves the use of freely 
diffusible ligands, which are only able to bind effectively in one 
of the isomeric forms.  Such compounds are known as 
photochromic ligands (PCL), and preclude the requirement for 
mutagenesis to incorporate reactive handles for covalent 
attachment.  
  Examples of PTLs and PCLs for GABAA receptors have been 
described recently in the literature. Propofol analogues have 
been designed as photochromic potentiators of GABAA 
receptors.10  Lin et al. have also described the use of an 
engineered GABAA receptor to enable the tethering of the 
agonist muscimol.  Rather than the expected agonism they 
observed antagonism using this PTL, which was also observed  
using guanidinium analogues of GABA.10c, d 
 
Figure 1. Gabazine, potent analogues and the targeted azogabazine as a 
photochromic antagonist of the GABAA receptor. 
Having previously established that elaboration of the gabazine 
molecule to incorporate benzyl substituents leads to enhanced 
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binding to the GABAA receptor (i.e. Gz-i1), we envisaged that 
this strategy could be harnessed for the design of potent 
antagonists as PCLs.  Following the ‘azologization’ approach 
pioneered by Trauner and co-workers11 we identified the benzyl 
ether in Gz-i1 (Fig. 1) as being an ideal structural motif to be 
replaced by an azobenzene photoswitch.   Thus we targeted 
‘azogabazine’ as a prospective new tool for this important class 
of ion channels.   
 The synthesis of azogabazine was accomplished in just five 
synthetic steps (scheme 1).  Condensation of aniline 1 with 
nitrosobenzene was followed by conversion of the boronate 
ester into the trifluoroborate salt 2.  Suzuki reaction with 3-
amino-6-chloropyridazine12 afforded the triaryl intermediate 3, 
which underwent N(2) alkylation and subsequent deallylation to 
afford azogabazine.  The overall yield for the sequence was 16%. 
 
 
Scheme 1.Synthesis of azogabazine 
  Azogabazine was tested for potency on α1β2γ2 GABAA 
receptors expressed in HEK293 cells, using whole-cell patch-
clamp recording, and proved to be one of the most potent GABA 
antagonists known (Fig. 2).  An IC50 of 23 nM was determined, 
representing a 13-fold improvement over gabazine. This 
enhanced potency is similar to that observed with Gz-i1, 
suggesting that the benzyl phenyl ether and azobenzene 
represented ideal bioisosteres in this application.   
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Concentration inhibition curve for azogabazine. Azogabazine 
was applied in combination with 10 µM GABA. pIC50: 7.646 +/- 0.141, n = 
6 (IC50: 22.6 nM). 
 
UV/Vis absorbance spectra were taken to confirm the retention 
of azobenzene absorbance characteristics.  The initial spectrum 
was consistent with the thermodynamically favoured trans- 
azogabazine, showing a characteristic large absorbance with 
λmax of 342 nm representing a π→π* transition. After 30 s of 
irradiation with a hand-held torch containing LEDs of 365 nm a 
further UV spectrum was taken (Fig. 3). This was now 
characteristic of a cis azobenzene-containing compound, with 
an increase in absorbance at 435 nm and a concomitant 
decrease at lower wavelengths.  
1H-NMR studies confirmed this photoswitching behaviour and 
allowed quantification of the ratios at photostationary states.  
Irradiation with a UV light (a 365 nm LED) afforded the cis-
enriched photostationary state in a 5 : 1 ratio.  By contrast 
irradiation with blue light (a 470 nm LED) afforded 
predominantly the trans product in a 3 : 1 ratio.  No further 
changes were seen after 60 s irradiation in each case, showing 
the interconversions to form the photostationary states to be 
rapid.   Once formed, the cis isomer was found to show slow 
thermal conversion to the more stable trans isomer, requiring 
20 days in the dark to achieve full conversion; thus representing 
a high bistability system. 
     
Figure 3. Overlaid UV/Vis absorbance spectra for i) sample of azogabazine 
(orange) representing the trans isomer and ii) sample of UV irradiated 
azogabazine (red) representing the cis isomer. 
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Azogabazine was then constantly perfused onto GABAA 
receptor expressing HEK cells, along with 10 μM GABA, followed 
by alternating application of blue (a 470 nm LED) and UV light 
(a 365 nm LED; Fig. 4).  Each cycle of blue light led to reduced 
currents, confirming that the predominating trans isomer was 
serving as the most potent antagonist.  In contrast, UV light 
produced an inward current, as the cis azogabazine was 
generated and no longer served as an effective antagonist.  Thus 
after presumed ejection from the GABA binding sites GABA-
mediated activation was taking place. 
 
Figure 4. Whole-cell GABA currents recorded from α1β2γ2 GABAA 
receptors expressed in a HEK cell. Upper panel: cell exposed to Krebs (bar) 
and alternating periods of blue and UV light which do not induce current 
responses. Lower panel: The control 10µM GABA current (left) is reduced in 
the presence of co-applied azobenzene, and GABA currents are only revealed 
by exposure to UV light (Right).   
Conclusions 
We have described the design and convenient synthesis of 
azogabazine, a potent photochromic antagonist of the GABAA 
receptor.  This study represents a powerful demonstration of 
the ‘azologization’ strategy for the design of photochromic 
ligands.  The identification of a benzyl phenyl ether as an 
‘azostere’ guided our strategy for the introduction of the 
azobenzene motif, and resulted in an antagonist which was 13 
times more potent than gabazine itself. Repeated cycling from 
blue-to-UV light showed robust photo-control of GABAA 
receptor channel activity making azogabazine a useful new 
research tool for studying GABAA receptors.  
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